Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 600 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22–23

HOS-225431 · Präparat HOS-217440

22 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with Cmax, Cmin with 90% Efavirenz/Emtricitabine/Tenofo confidence intervals if vir disoproxil Zentiva (efavirenz available (mechanism) 600 mg, emtricitabine 200 mg, tenofovir disoproxil 245 mg) Antimycobacterials Rifabutin/efavirenz Rifabutin: The daily dose of rifabutin should (300 mg q.d./600 mg q.d.) AUC: ↓ 38% (↓ 28 to ↓ 47) be increased by 50% when given Cmax: ↓ 32% (↓ 15 to ↓ 46) with Cmin: ↓ 45% (↓ 31 to ↓ 56) Efavirenz/Emtricitabine/Tenofovi r disoproxil Zentiva. Consider Efavirenz: doubling the rifabutin dose in AUC: ↔ regimens where rifabutin is given Cmax: ↔ 2 or 3 times a week in Cmin: ↓ 12% (↓ 24 to ↑ 1) combination with (CYP3A4 induction) Efavirenz/Emtricitabine/Tenofovi Rifabutin/emtricitabine Interaction not studied. r disoproxil Zentiva. The clinical Rifabutin/tenofovir Interaction not studied. effect of this dose adjustment has disoproxil not been adequately evaluated. Individual tolerability and virological response should be considered when making the dose adjustment (see section 5.2). Rifampicin/efavirenz Efavirenz: When (600 mg q.d./600 mg q.d.) AUC: ↓ 26% (↓ 15 to ↓ 36) Efavirenz/Emtricitabine/Tenofovi Cmax: ↓ 20% (↓ 11 to ↓ 28) r disoproxil Zentiva is taken with Cmin: ↓ 32% (↓ 15 to ↓ 46) rifampicin in patients weighing (CYP3A4 and CYP2B6 50 kg or greater, an additional induction) 200 mg/day (800 mg total) of Rifampicin/tenofovir Rifampicin: efavirenz may provide exposure disoproxil AUC: ↔ similar to a daily efavirenz dose (600 mg q.d./245 mg q.d.) Cmax: ↔ of 600 mg when taken without rifampicin. The clinical effect of Tenofovir: this dose adjustment has not been AUC: ↔ adequately evaluated. Individual Cmax: ↔ tolerability and virological Rifampicin/emtricitabine Interaction not studied. response should be considered when making the dose adjustment (see section 5.2). No dose adjustment of rifampicin is recommended when given with Efavirenz/Emtricitabine/Tenofovi r disoproxil Zentiva.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) rifabutin (HOS-086262) tenofovir disoproxil (HOS-108843)